Business
Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers from Cardio Diagnostics and Dr. Damon Broyles published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally, a leading cause of death worldwide in the journal Epigenomics.\n\n\nThis review lays out an affordable, scalable framework to use artificial intelligence-guided epigenetic assessments for CHD risk assessment, diagnosis, and management. The digital PCR-based approach requires only minimal infrastructure investments while providing unparalleled personalized biological insights into the drivers of each patient's CHD presentation.\n\n\nAccording to the manuscript published online on September 13th, current diagnostic methods like angiograms and exercise ECGs have significant limitations with respect to sensitivity, scalability, and assessment-related morbidity. These difficulties increase the real-world cost of these tests and hinder the use of these tests in developing economies or rural areas.\n\n\nIn response to these challenges, the Broyles’ led review describes a potentially disruptive blood-based DNA test, PrecisionCHD™. This test uses easily performed digital PCR laboratory assays to quantify epigenetic signatures that are interpreted by artificial intelligence (AI) to determine the presence or absence of CHD. Though it required years of development, the PrecisionCHD™ test can now be performed within hours using standard laboratory equipment.\n\n\n\"Without a doubt, the future in precision epigenetics for diagnosing and managing CHD is bright. We stand on the cusp of a transformative era, with the potential to bring high-quality CHD care to all corners of the globe,” noted lead author Damon Broyles, MD, the VP of Clinical Innovation, Medical Director of Precision Medicine and Vice Chair of Mercy Board of Research.\n\n\n\"Our research shows a clear pathway for precision epigenetics to fill critical unmet needs in cardiac care on a national and global scale,\" said Dr. Robert Philibert, Chief Medical Officer and Co-Founder of Cardio Diagnostics. \"Combining next-generation epigenomics and AI enables earlier CHD detection, improved ris...